Tag: Abbott

August 15, 2022

Abbott is facing increased competition from Dexcom in Europe, which received a CE mark for its G7 device in March and began a commercialization strategy that initially targeted large markets such as Germany and the U.K. Abbott has been expanding […]

July 9, 2021

What a difference a year makes for Abbott’s COVID-19 testing business. Abbott in May 2020 announced it was expanding its Maine workforce to Westbrook to ramp up production of rapid coronavirus test kits by leasing a former sporting goods distribution […]

June 28, 2021

Abbott is betting that frequent rapid COVID-19 testing at work, school and home are critical to enabling European economies to fully reopen and to allow daily life activities to resume. With CE mark approval for the direct-to-consumer Panbio, the diagnostics […]

January 23, 2019

Abbott (NYSE:ABT) stock is down about 2% at the opening of trading today after its fourth-quarter sales failed to meet analyst expectations. The Abbott Park, Ill.–based maker of medical device, pharmaceutical, nutrition and diagnostics products brought in about $7.765 billion […]

January 16, 2019

Abbott (NYSE:ABT) said today that it plans to acquire mitral heart valve replacement tech developer Cephea Valve Technologies for an undisclosed amount. The Chicago-area healthcare giant backed the Santa Clara, Calif.-based valve company in July 2015 and secured an option […]

January 3, 2019

Several medical device companies took hits yesterday after analysts on Wall Street downgraded their stocks, on a day when the major market indices each closed up a hair, and even medtech firms that enjoyed upgrades came under pressure. Globus Medical […]

July 18, 2018

Abbott (NYSE:ABT) today reported second-quarter results that came in ahead of the consensus expectation, with its medical device division posting sales growth of more than 11%, and raised its earnings outlook for the rest of the year. The Chicago-area healthcare […]

July 12, 2018

Abbott (NYSE:ABT) won FDA approval for the third generation of its MitraClip transcatheter heart valve repair device, the company said today. Acquired in the $410 million acquisition of Evalve back in 2009, MitraClip won its first FDA nod in 2013. […]